Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.

DOI:10.1016/S1470-2045(26)00282-2
作者：Xiuning Le,?Antonio Passaro,?Yuanyuan Zhao,?Yan Huang,?Janessa Laskin,?Delvys Rodriguez-Abreu,?Antonio Calles,?Lyudmila Bazhenova,?Giuseppe Lo Russo,?Natasha B Leighl,?Federico Cappuzzo,?Nicolas Girar
文献类型：期刊论文
补充材料：只需要正文